Trial Profile
A Phase I/IIa Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients With Advanced, Unresectable Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Plixorafenib (Primary)
- Indications Cholangiocarcinoma; Colorectal cancer; Hairy cell leukaemia; Malignant melanoma; Non-small cell lung cancer; Solid tumours; Thyroid cancer
- Focus Adverse reactions
- Sponsors Plexxikon
- 15 Sep 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 18 Apr 2014 Planned number of patients changed from 42 to 172 as reported by ClinicalTrials.gov record.
- 18 Apr 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.